secwatch.observer — SEC 8-K summary
======================================

Issuer:     BNB PLUS CORP. (BNBX)
CIK:        0000744452
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001104659-23-059126
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Applied DNA Q2 FY2023 revenue falls 28% to $4.4M; identifies mRNA acquisition target
--------------------------------------------------------------------------------

- Total revenues $4.4M, down from $6.1M YoY; COVID-19 testing revenue declined $1.5M.
- Operating loss $2.7M vs $2.2M prior year; Adjusted EBITDA -$2.1M vs -$1.6M.
- Cash $12.3M as of March 31, 2023, down from $15.2M in December 2022.
- Identified mRNA value chain acquisition target; expects closing by June 30, 2023.
- Submitted PGx assay validation to NYSDOH; approval anticipated in coming months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744452/000110465923059126/0001104659-23-059126-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744452/000110465923059126/tm2315498d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-059126

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer